To corroborate the requirement for LIMK activity in neuroblastoma cells, we knocked down LIMK1 and LIMK2, either by combining two siRNA oligonucleotides (LIMK1+LIMK2) or using an siRNA oligonucleotide (panLIMK) that reduces expression of both proteins, in SK-N-AS and SK-N-SH cells (Figure 10C). The gene discussed is LIMK1; the disease is neuroblastoma.